| Stage | CRCT | % of rev | LRCX | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $156M | 100.00% | $8.2B | 100.00% | LRCX ×52.59 |
| Gross profit | $116M | 74.48% | $4.3B | 52.30% | CRCT +22.2pp |
| Operating income | $47M | 30.34% | $3.3B | 39.95% | LRCX +9.6pp |
| Pre-tax income | $50M | 32.19% | $3.3B | 40.30% | LRCX +8.1pp |
| Net income | $39M | 24.99% | $2.8B | 33.50% | LRCX +8.5pp |
| Stage | CRCT | LRCX | Gap · A − B |
|---|---|---|---|
| Revenue | $156M100.00% | $8.2B100.00% | LRCX ×52.59 |
| Gross profit | 74.48%$116M | 52.30%$4.3B | CRCT +22.2pp |
| Operating income | 30.34%$47M | 39.95%$3.3B | LRCX +9.6pp |
| Pre-tax income | 32.19%$50M | 40.30%$3.3B | LRCX +8.1pp |
| Net income |
| 24.99%$39M |
| 33.50%$2.8B |
| LRCX +8.5pp |
No shared counterparties.